NASDAQ:BJDX Bluejay Diagnostics Q3 2025 Earnings Report $0.90 -0.11 (-11.16%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$0.86 -0.04 (-4.71%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bluejay Diagnostics EPS ResultsActual EPS-$4.04Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABluejay Diagnostics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABluejay Diagnostics Announcement DetailsQuarterQ3 2025Date11/7/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsBluejay Diagnostics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Bluejay Diagnostics Earnings Headlines5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & AtaraSeptember 8, 2026 | rttnews.comBluejay Diagnostics federal healthcare partnership builds commercial pathway ahead of FDA clearanceSeptember 8, 2026 | msn.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 13 at 1:00 AM | Chaikin Analytics (Ad)Bluejay Diagnostics, Lovell Team Up To Access U.S. Federal Healthcare MarketSeptember 8, 2026 | rttnews.comBluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare MarketsSeptember 8, 2026 | markets.businessinsider.comBluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare MarketsSeptember 8, 2026 | globenewswire.comSee More Bluejay Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email. Email Address About Bluejay DiagnosticsBluejay Diagnostics (NASDAQ:BJDX) (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures. Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting. The company has been pursuing clinical validation studies and regulatory clearances to support its plans for commercialization, working to demonstrate accuracy, reliability, and ease of use in both clinical and at-home environments. Headquartered in Norcross, Georgia, Bluejay Diagnostics serves the U.S. market with strategic plans to expand internationally once regulatory approvals and distribution partnerships are in place. The management team brings together expertise in diagnostics, biotech development, and regulatory affairs, positioning the company to navigate the complex pathways associated with medical device registration and market entry. As Bluejay advances its development pipeline, it aims to improve patient access to timely, accurate, and patient-friendly diagnostic solutions for celiac disease and related disorders.View Bluejay Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
